About this trial
Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experiment performed separately in people with T2DM.
Eligibility criteria
Qualifiers
We will recruit up to 20 weight-stable, subjects with type 2 diabetes
BMI ≥ 28 Kg/M2
Diabetes is managed by diet alone or a combination of oral agents
Disqualifiers
History of prior upper abdominal surgery e.g. gastric banding, pyloroplasty, vagotomy.
Active systemic illness or malignancy.
Symptomatic macrovascular or microvascular disease.
Contraindications to MRI (e.g. metal implants, claustrophobia).
Trial design
Treatments tested in this trial
- Caloric Restriction
- Hyperglycemic clamp
Treatment groups
Locations
1Sponsors and collaborators
Adrian Vella
Lead sponsor
Mayo Clinic
Sponsor institution